吸入氢气对心脏骤停后脑缺血神经功能结局的疗效(HYBRID II试验):随机对照试验研究方案
HYBRID II是一项由研究者发起的随机双盲安慰剂对照试验,计划纳入360例院外心脏骤停复苏后昏迷的成年患者,随机分为吸入2%氢气组与对照组,主要评价90天神经功能结局(CPC评分)。该研究旨在确认氢气吸入对心脏骤停后综合征患者神经功能结局的疗效。
要点
- 纳入360例院外心脏骤停复苏后昏迷(GCS<8)的成年患者。
- 氢气组吸入2%氢气与24%至50%氧气,对照组吸入24%至50%氧气,均18小时。
- 主要结局为90天CPC评估的神经功能结局。
核心结论
- 正在开展首个多中心随机试验,以确认氢气吸入对院外心脏骤停复苏后昏迷幸存者神经功能结局的疗效。
- 研究有望将氢气吸入联合目标温度管理作为心脏骤停后综合征有吸引力和创新的治疗策略。
研究设计与样本
- 研究者发起的随机双盲安慰剂对照试验,计划纳入360例院外心脏骤停(推测心源性)复苏后昏迷(GCS<8)的成年患者。
- 患者按1:1随机分为氢气吸入组或对照组。
- 氢气组吸入2%氢气与24%至50%氧气,对照组吸入24%至50%氧气,入监护后经机械通气吸入18小时。
- 按最新指南提供多学科心脏骤停后治疗,包括33°C至36°C的目标温度管理。
主要发现
- 本研究为方案,尚未报告疗效结果。
- 样本量计算:以80%把握度检测神经功能良好(CPC 1和2)患者比例从50%至65%的15%变化,总体显著性水平0.05。
关键数值与推荐
- 主要结局为90天神经功能结局,采用大脑功能分类量表(CPC)评估。
- 次要结局为90天生存率及其他神经功能结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hydrogen gas inhalation (HI) improved survival and neurological outcomes in an animal model of post-cardiac arrest syndrome (PCAS). The feasibility and safety of HI for patients with PCAS was confirmed in a pilot study. The objective of this study is to evaluate the efficacy of HI for patients with PCAS. METHODS/DESIGN: The efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During post-cardiac arrest care (HYBRID II) trial is an investigator-initiated, randomized, double-blind, placebo-controlled trial designed to enroll 360 adult comatose (Glasgow Coma Scale score < 8) patients who will be resuscitated following an out-of-hospital cardiac arrest of a presumed cardiac cause. The patients will be randomized (1:1) to either the HI or control group. Patients in the HI group will inhale 2% hydrogen with 24% to 50% oxygen, and those in the control group will inhale 24% to 50% oxygen for 18 h after admission via mechanical ventilation. Multidisciplinary post-arrest care, including targeted temperature management (TTM) between 33 °C and 36 °C, will be provided in accordance with the latest guidelines. The primary outcome of interest is the 90-day neurological outcome, as evaluated using the Cerebral Performance Categories scale (CPC). The secondary outcomes of interest are the 90-day survival rate and other neurological outcomes. This study will provide 80% power to detect a 15% change in the proportion of patients with good neurological outcomes (CPCs of 1 and 2), from 50% to 65%, with an overall significance level of 0.05. DISCUSSION: The first multicenter randomized trial is underway to confirm the efficacy of HI on neurological outcomes in comatose out-of-hospital cardiac arrest survivors. Our study has the potential to address HI as an appealing and innovative therapeutic strategy for PCAS in combination with TTM. TRIALS REGISTRATION: University Hospital Medical Information Network (UMIN), 000019820 . Registered on 17 November 2015.
引用
- Tamura T, Hayashida K, Sano M, et al. Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During post-cardiac arrest care (HYBRID II trial): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29058596. doi:10.1186/s13063-017-2246-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。